Myriad Genetics Inc (MYGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Myriad Genetics Inc (MYGN) has a cash flow conversion efficiency ratio of -0.047x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.70 Million) by net assets ($337.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Myriad Genetics Inc balance sheet independence to measure how much of total assets are equity-financed.
Myriad Genetics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Myriad Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MYGN cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Myriad Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Myriad Genetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Huaming Intelligent Terminal Equipment Co Ltd
SHE:300462
|
0.029x |
|
Wireless Power Amplifier Module Inc
KQ:332570
|
-0.129x |
|
Hutchison Telecommunications (Australia) Ltd
AU:HTA
|
0.783x |
|
Accent Group Ltd
AU:AX1
|
0.214x |
|
Zhejiang HISUN Biomaterials Co. Ltd. A
SHG:688203
|
N/A |
|
Samudera Indonesia Tbk
JK:SMDR
|
0.047x |
|
NCT Alliance Bhd
KLSE:0056
|
-0.022x |
|
Polaris Media
OL:POL
|
0.072x |
Annual Cash Flow Conversion Efficiency for Myriad Genetics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Myriad Genetics Inc from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see MYGN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $368.00 Million | $1.80 Million | 0.005x | +139.42% |
| 2024-12-31 | $701.10 Million | $-8.70 Million | -0.012x | +91.24% |
| 2023-12-31 | $783.20 Million | $-110.90 Million | -0.142x | -17.99% |
| 2022-12-31 | $885.80 Million | $-106.30 Million | -0.120x | -724.41% |
| 2021-12-31 | $967.80 Million | $18.60 Million | 0.019x | -79.77% |
| 2020-12-31 | $881.00 Million | $83.70 Million | 0.095x | +23.60% |
| 2019-12-31 | $1.09 Billion | $83.70 Million | 0.077x | -36.01% |
| 2018-12-31 | $964.90 Million | $115.90 Million | 0.120x | -12.03% |
| 2017-12-31 | $777.80 Million | $106.20 Million | 0.137x | -38.58% |
| 2016-12-31 | $748.10 Million | $166.30 Million | 0.222x | +4.76% |
| 2015-12-31 | $662.10 Million | $140.50 Million | 0.212x | -19.78% |
| 2014-12-31 | $719.00 Million | $190.20 Million | 0.265x | +10.83% |
| 2013-12-31 | $728.59 Million | $173.90 Million | 0.239x | +6.99% |
| 2012-12-31 | $635.66 Million | $141.80 Million | 0.223x | -3.35% |
| 2011-12-31 | $566.79 Million | $130.83 Million | 0.231x | -17.01% |
| 2010-12-31 | $557.58 Million | $155.09 Million | 0.278x | +43.71% |
| 2009-12-31 | $434.22 Million | $84.04 Million | 0.194x | -20.58% |
| 2008-12-31 | $425.65 Million | $103.74 Million | 0.244x | +420.88% |
| 2007-12-31 | $340.36 Million | $-25.85 Million | -0.076x | +32.31% |
| 2006-12-31 | $249.78 Million | $-28.03 Million | -0.112x | +34.67% |
| 2005-12-31 | $135.67 Million | $-23.30 Million | -0.172x | +3.62% |
| 2004-12-31 | $173.28 Million | $-30.88 Million | -0.178x | +37.40% |
| 2003-12-31 | $163.49 Million | $-46.54 Million | -0.285x | -124.90% |
| 2002-12-31 | $128.87 Million | $-16.31 Million | -0.127x | -367.92% |
| 2001-12-31 | $139.56 Million | $-3.78 Million | -0.027x | -112.25% |
| 2000-12-31 | $77.71 Million | $17.16 Million | 0.221x | +175.51% |
| 1999-12-31 | $48.20 Million | $-14.10 Million | -0.293x | -140.29% |
| 1998-12-31 | $57.50 Million | $-7.00 Million | -0.122x | -22.11% |
| 1997-12-31 | $66.20 Million | $-6.60 Million | -0.100x | -599.91% |
| 1995-12-31 | $70.20 Million | $1.40 Million | 0.020x | -- |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more